Helicon Group Secures Milestone Regulatory Approval In China For Skin Regeneration Medical Technology ReCell(R)

July 3, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Perth, July 3, 2008 (ABN Newswire) - HELICON GROUP LIMITED (ASX:HCG) today announced that the Chinese State Food and Drug Administration (SFDA) has granted approval for the skin regeneration concept and device, ReCell(R).

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Australia